Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013

Sagara Y., Freedman R. A., Wong S. M., Aydogan F., Nguyen A., Barry W. T., ...Daha Fazla

BREAST CANCER RESEARCH AND TREATMENT, cilt.166, sa.2, ss.583-592, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 166 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1007/s10549-017-4436-9
  • Dergi Adı: BREAST CANCER RESEARCH AND TREATMENT
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.583-592
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Breast-conserving surgery (BCS) followed by radiotherapy (RT) with or without endocrine therapy (ET) is a standard treatment option for ductal carcinoma in situ (DCIS). We sought to investigate national patterns in the use of adjuvant therapy after BCS for hormone receptor (HR)-positive DCIS over time.